4'-Thio-araC (Thiarabine) in Advanced Hematologic Malignancies
Phase 1
Completed
- Conditions
- Leukemia
- Interventions
- Drug: 3 Day ThiarabineDrug: 5 Day Thiarabine
- First Posted Date
- 2010-06-08
- Last Posted Date
- 2014-06-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT01139151
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
Phase 2
Completed
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Drug: CMC-544 (Inotuzumab Ozogamycin)
- First Posted Date
- 2010-06-02
- Last Posted Date
- 2024-07-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 90
- Registration Number
- NCT01134575
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Radical Pleurectomy/Decortication (PD) and Intensity Modulated Radiotherapy (IMRT)
Phase 1
Completed
- Conditions
- Lung CancerMesothelioma
- Interventions
- Radiation: IMRT
- First Posted Date
- 2010-05-31
- Last Posted Date
- 2017-07-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT01134146
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Survivorship in Lynch Syndrome Families
Completed
- Conditions
- Colorectal Cancer
- Interventions
- Behavioral: Telephone InterviewBehavioral: Questionnaire
- First Posted Date
- 2010-05-20
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 303
- Registration Number
- NCT01126840
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
Phase 1
Completed
- Conditions
- Kidney CancerRenal Cell Cancer
- Interventions
- First Posted Date
- 2010-05-13
- Last Posted Date
- 2015-11-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT01122615
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Ipilimumab + Temozolomide in Metastatic Melanoma
- First Posted Date
- 2010-05-07
- Last Posted Date
- 2024-06-06
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 64
- Registration Number
- NCT01119508
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Pleural Catheters Versus Thoracoscopic Pleurodesis
Completed
- Conditions
- Lung Cancer
- Interventions
- Behavioral: MDASI Questionnaire
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2016-04-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 445
- Registration Number
- NCT01117740
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
TPI 287 in Patients With Recurrent Glioblastoma Multiforme
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 17
- Registration Number
- NCT01113463
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies
Phase 1
Completed
- Conditions
- Advanced Cancer
- Interventions
- First Posted Date
- 2010-04-30
- Last Posted Date
- 2022-09-02
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 176
- Registration Number
- NCT01113476
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Phase I / II Vorinostat, Erlotinib and Temozolomide for Recurrent Glioblastoma Multiforme (GBM)
Phase 1
Terminated
- Conditions
- Brain CancerGlioblastoma Multiforme
- Interventions
- First Posted Date
- 2010-04-27
- Last Posted Date
- 2021-08-25
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 21
- Registration Number
- NCT01110876
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States